FridaySep 20, 2024 3:18 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. “Lexaria has recently made strides with glucagon-like peptide-1 (‘GLP-1’) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes and obesity. Recently, the company announced the dosing completion of its human pilot study #2, GLP-1-H24-2, which sought to explore effective oral delivery of GLP-1 drugs. Some evaluated aspects included side effects, blood levels of…

Continue Reading

FridaySep 20, 2024 1:39 pm

TinyGemsBreaks – SBC Medical Group Holdings Inc. (NASDAQ: SBC) Completes Business Combination with Pono Capital Two, Begins Trading on Nasdaq

SBC Medical Group Holdings Inc. (NASDAQ: SBC), a global provider of cosmetic treatment management services, has successfully completed its business combination with Pono Capital Two, which was approved on August 23, 2024. Following the merger's closure on September 17, 2024, SBC Medical's shares and warrants began trading on Nasdaq under the ticker symbols ‘SBC’ and ‘SBCWW,’ respectively. The company plans to utilize the new capital to drive expansion in the U.S. and Southeast Asia, while continuing to strengthen its established presence in Japan. “We are focused on providing premium care and value to our customers and their patients through transformative…

Continue Reading

FridaySep 20, 2024 12:55 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Officials in UAE to Support Volt Mobility $210M Order

Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, is sharing an update regarding a Volt Mobility United Arab Emirates (“UAE”) order valued at up to $210 million; the order is for 300 Mullen Class 1 and Class 3 electric vehicles. According to the update, members of the company’s technical and sales team are on site in Dubai this week, meeting with Volt officials, providing support for initial market launch activities, and overseeing delivery of the first Mullen One EV cargo vans and Mullen Three cab chassis trucks. Mullen is working with the Miami-based VoltiE Group, a charging company, to…

Continue Reading

TuesdaySep 17, 2024 12:07 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Inks Sales, Service Agreement with Leading Commercial Dealer Group

Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, is adding to its EV dealership network. According to the company, premier full-service dealer Papé Kenworth has become Mullen’s seventh franchise dealer partner. Based in Eugene, Oregon, Papé Kenworth, which is part of the Papé Group, has more than 30 locations and is the West's premiere, full-service Kenworth truck dealer. The dealership is partnering with Mullen to provides zero-emissions trucks for a wide range of applications as it supports customers that are adapting to comply with evolving regulations. “Papé Kenworth is a hallmark dealer and distributor with unmatched and deep experience…

Continue Reading

TuesdaySep 17, 2024 9:00 am

TinyGemsBreaks – NextPlat Corp. (NASDAQ: NXPL) Reports on Voting Held During Annual Meeting of Stockholders

NextPlat (NASDAQ: NXPL), a global e-commerce provider, has released the voting results from its Special Annual Meeting of Stockholders, which was held Sept. 13, 2024. According to the report, shareholder voted on six agenda items, including a proposal to approve and adopt the merger agreement and plan of reorganization making Progressive Care Inc. (OTCQB: RXMD) a wholly owned subsidiary of the company. The proposal was approved, with an anticipated closing date of Oct. 1, 2024. The announcement noted that Progressive Care shareholders also approved the business combination at a special meeting of shareholders held Sept. 13, 2024. Other items approved…

Continue Reading

FridaySep 13, 2024 3:36 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). “Of note was growth in cash and marketable securities from $1.5 million during the same period in the 2023 financial year to $8.5 million as of May 31, 2024. The company reduced certain R&D expenditures and experienced other savings,” reads a recent article. “Most importantly, however, were the program updates for initiatives it embarked on for 2024. A highlight of its projects has been its glucagon-like peptide-1 (‘GLP-1’) agonist research program. GLP-1, a class of drugs, has demonstrated an…

Continue Reading

FridaySep 13, 2024 1:34 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) to Effect 1-for-100 Reverse Stock Split

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it will implement a 1-for-100 reverse stock split of its common stock, par value $0.001 per share, automatically combining and converting 100 current shares of its common stock into one issued and outstanding share of common stock. The reverse stock split, approved by the company’s stockholders and the board of directors, will take effect on September 17, 2024, at 12:01 a.m. ET. Following the split, the new CUSIP number will be 62526P505, with Mullen’s common stock trading on a split-adjusted basis under the existing ticker symbol MULN.…

Continue Reading

WednesdaySep 11, 2024 11:10 am

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Subsidiary Gains ‘Strong Foothold’ in California’s Central Valley on Newly Named Dealer

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that its subsidiary, Bollinger Motors, has added Affinity Truck Center, a family-owned business founded in 1980, to its retail network. As a result, Affinity, which operates sales locations in Bakersfield and Fresno, California, as well as service locations in Paso Robles and Salinas, California, is now an official Bollinger Motors dealer. Affinity is headquartered in the heart of California’s Central Valley. “The addition of Affinity Truck Center gives Bollinger Motors a strong foothold in California’s Central Valley,” commented Jim Connelly, chief revenue officer of Bollinger. “Affinity has a…

Continue Reading

MondaySep 09, 2024 11:46 am

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Subsidiary Achieves ‘Important Accomplishment’ with CARB Certification

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that its subsidiary, Bollinger Motors, has received certification from the California Air Resources Board (“CARB”) for its B4 all-electric, Class 4 low forward chassis truck. The CARB certification is a requirement to sell vehicles in California, Colorado, Connecticut, Delaware, Maine, Maryland, Massachusetts, New Jersey, New Mexico, New York, Oregon, Pennsylvania, Rhode Island, Vermont and the District of Columbia. According to the announcement, the certification opens B4 EV truck customers to federal and state incentives of up to $100,000. Bollinger plans to start production of the B4 on September…

Continue Reading

FridaySep 06, 2024 9:59 am

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, provided a strategic letter from outgoing CEO Chris Bunka updating all stakeholders. In the strategic update, Bunka discussed Lexaria’s performance in the capital markets; the company’s Phase 1b DehydraTECH-CBD hypertension trial and Australian-registered Phase 1b DehydraTECH-GLP-1 diabetes and weight-loss study; ongoing R&D; and his reason for stepping aside from his role as CEO. “It is because of the combination of events that include our successful money-raising, our R&D success, our new relationship with one pharmaceutical company and continued pursuit of others, and our confidence in our strategic direction…

Continue Reading

Contact us: (512) 354-7000